PMID- 9815666
OWN - NLM
STAT- MEDLINE
DCOM- 19990216
LR  - 20231213
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 3
IP  - 2
DP  - 1997 Feb
TI  - Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a 
      new target for a potent Pseudomonas exotoxin-based chimeric toxin protein.
PG  - 151-6
AB  - AIDS-associated Kaposi's sarcoma (AIDS-KS), the most common malignant 
      complication of human immunodeficiency virus infection, is characterized by 
      neoplastic proliferation of mesenchymal cells. AIDS-KS cells release and respond 
      to an array of cytokines through specific plasma membrane receptors. Specific 
      targeting of potent cytotoxic agents to cell surface receptors/antigens on 
      Kaposi's sarcoma cells may provide effective therapy for this malignancy. We have 
      identified a new target in the form of an interleukin 13 (IL-13) receptor that is 
      overexpressed in the five AIDS-KS cell lines examined. Radiolabeled IL-13 
      cross-linked to a single protein of about Mr 70,000 in AIDS-KS cells. We utilized 
      a chimeric cytotoxic protein composed of IL-13 and a truncated Pseudomonas 
      exotoxin (IL13-PE38QQR), which was found to be specifically and highly cytotoxic 
      to AIDS-KS cells, as determined by protein synthesis inhibition and clonogenic 
      assays. IL13-PE38QQR demonstrated significant antitumor activity in a human 
      epidermoid carcinoma xenograft model. Normal human umbilical vein-derived 
      endothelial, lymphoid, and bone marrow precursor cells expressed low levels of 
      IL-13 receptors, and IL-13 toxin was not cytotoxic to them. Thus, IL-13 receptor 
      on AIDS-KS cells may represent a novel plasma membrane protein(s) that could be 
      utilized to target therapeutic agents.
FAU - Husain, S R
AU  - Husain SR
AD  - Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, 
      Center for Biologics Evaluation and Research, Food and Drug Administration, 
      Bethesda, Maryland 20892, USA.
FAU - Obiri, N I
AU  - Obiri NI
FAU - Gill, P
AU  - Gill P
FAU - Zheng, T
AU  - Zheng T
FAU - Pastan, I
AU  - Pastan I
FAU - Debinski, W
AU  - Debinski W
FAU - Puri, R K
AU  - Puri RK
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Bacterial Toxins)
RN  - 0 (Exotoxins)
RN  - 0 (IL13RA1 protein, human)
RN  - 0 (Immunotoxins)
RN  - 0 (Interleukin-13)
RN  - 0 (Interleukin-13 Receptor alpha1 Subunit)
RN  - 0 (Protein Synthesis Inhibitors)
RN  - 0 (Receptors, Interleukin)
RN  - 0 (Receptors, Interleukin-13)
RN  - 0 (Virulence Factors)
RN  - EC 2.4.2.- (ADP Ribose Transferases)
SB  - IM
MH  - *ADP Ribose Transferases
MH  - AIDS-Related Opportunistic Infections/drug therapy/*metabolism
MH  - Antineoplastic Agents/*pharmacology
MH  - *Bacterial Toxins
MH  - Exotoxins/*pharmacology
MH  - Humans
MH  - Immunotoxins/immunology/*pharmacology
MH  - Interleukin-13/*metabolism/pharmacology
MH  - Interleukin-13 Receptor alpha1 Subunit
MH  - Protein Synthesis Inhibitors/pharmacology
MH  - Receptors, Interleukin/*biosynthesis/drug effects
MH  - Receptors, Interleukin-13
MH  - Sarcoma, Kaposi/drug therapy/immunology/*metabolism
MH  - Tumor Cells, Cultured
MH  - Tumor Stem Cell Assay
MH  - *Virulence Factors
MH  - Pseudomonas aeruginosa Exotoxin A
EDAT- 1997/02/01 00:00
MHDA- 1998/11/17 00:01
CRDT- 1997/02/01 00:00
PHST- 1997/02/01 00:00 [pubmed]
PHST- 1998/11/17 00:01 [medline]
PHST- 1997/02/01 00:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 1997 Feb;3(2):151-6.